Tecentriq (atezolizumab)

pCPA File Number: 21167

Negotiation Status:

Concluded with an LOI

Indication(s):

Extensive stage small cell lung cancer (ES-SCLC), first-line treatment, in combination with a platinum-based chemotherapy and etoposide

Sponsor/Manufacturer:

Hoffmann-La Roche Ltd.

CDA-AMC Project Number:

PC0156-000

pCPA Engagement Letter Issued:

2021-09-27

Negotiation Process Concluded:

2022-02-11